Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $477M | $470M | $524M | $558M | $160M | $101M | $111M | $103M | $128M | $129M |
| Revenue growth | — | -1.5% | 11.6% | 6.4% | -71.3% | -37.0% | 10.3% | -7.2% | 24.2% | 0.5% |
| Gross profit | $66.8M | $79.2M | $78.3M | $81.0M | $39.4M | $38.9M | $39.1M | $28.0M | $41.9M | $40.3M |
| Gross margin | 14.0% | 16.9% | 14.9% | 14.5% | 24.6% | 38.6% | 35.1% | 27.1% | 32.6% | 31.3% |
| Operating income | -$20.6M | $14.7M | $13.6M | $5.47M | -$25.9M | -$8.82M | -$11.8M | -$21.8M | -$8.84M | -$17.2M |
| Operating margin | -4.3% | 3.1% | 2.6% | 1.0% | -16.2% | -8.7% | -10.6% | -21.1% | -6.9% | -13.4% |
| Net income | -$11.6M | $10.6M | $24.8M | $411K | -$38.2M | -$32.3M | -$117M | -$99.6M | $12.0M | -$38.7M |
| Net margin | -2.4% | 2.3% | 4.7% | 0.1% | -23.9% | -32.0% | -104.9% | -96.4% | 9.4% | -30.0% |
| EPS (diluted) | -$0.43 | $0.38 | $0.89 | $0.01 | -$1.31 | -$1.10 | -$3.97 | -$3.32 | $0.33 | -$1.27 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $20.8M | $29.8M | $19.8M | $16.0M | -$17.0M | $16.5M | -$22.6M | -$17.4M | $257K | -$206K |
| Capital expenditures | $39.7M | $23.0M | $33.6M | $44.7M | $12.2M | $19.3M | $26.2M | — | $18.4M | $13.4M |
| Free cash flow | -$18.9M | $6.83M | -$13.8M | -$28.7M | -$29.3M | -$2.79M | -$48.8M | — | -$18.1M | -$13.6M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $9.97M | $6.00M | $2.90M | $1.08M | $439K | $1.85M | $1.10M | $19.1M | $8.46M | $8.27M |
| Total assets | $343M | $359M | $405M | $519M | $503M | $507M | $324M | $254M | $254M | $239M |
| Total liabilities | $130M | $130M | $152M | $249M | $285M | $305M | $182M | $218M | $200M | $192M |
| Long-term debt | $53.8M | $47.2M | $42.3M | $97.0M | $113M | $165M | $98.2M | $84.8M | $125M | $130M |
| Shareholders' equity | $211M | $227M | $253M | $270M | $230M | $202M | $87.8M | -$4.23M | $11.3M | $1.34M |
| Retained earnings | $73.5M | $84.5M | $109M | $110M | $57.6M | $39.0M | -$23.7M | -$179M | -$167M | -$205M |
| Shares (wtd avg diluted) | 27.0M | 27.7M | 27.9M | 28.6M | 29.2M | 29.3M | 29.5M | 30.0M | 36.7M | 34.8M |
Every figure is extracted from LIFECORE BIOMEDICAL, INC. \DE\’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.